BioLine Rx Ltd (BLRX)
0.68
+0.02
(+3.01%)
USD |
NASDAQ |
May 03, 16:00
0.6783
0.00 (0.00%)
After-Hours: 20:00
BioLine Rx Cash from Financing (Quarterly): 11.74M for Dec. 31, 2023
Cash from Financing (Quarterly) Chart
Historical Cash from Financing (Quarterly) Data
| Date | Value |
|---|---|
| December 31, 2023 | 11.74M |
| September 30, 2023 | 3.499M |
| June 30, 2023 | -0.134M |
| March 31, 2023 | -0.049M |
| December 31, 2022 | -0.647M |
| September 30, 2022 | 22.72M |
| June 30, 2022 | -0.689M |
| March 31, 2022 | -0.943M |
| December 31, 2021 | 0.174M |
| September 30, 2021 | 1.575M |
| June 30, 2021 | 14.09M |
| March 31, 2021 | 41.91M |
| December 31, 2020 | 6.947M |
| September 30, 2020 | -1.048M |
| June 30, 2020 | 11.58M |
| March 31, 2020 | 0.387M |
| December 31, 2019 | 2.592M |
| September 30, 2019 | 0.879M |
| June 30, 2019 | 0.806M |
| March 31, 2019 | 14.92M |
| December 31, 2018 | 10.28M |
| September 30, 2018 | 0.018M |
| June 30, 2018 | 1.40M |
| March 31, 2018 | 1.40M |
| December 31, 2017 | 0.989M |
| Date | Value |
|---|---|
| September 30, 2017 | 9.426M |
| June 30, 2017 | 26.20M |
| March 31, 2017 | 2.064M |
| December 31, 2016 | 0.566M |
| September 30, 2016 | -0.023M |
| June 30, 2016 | -0.025M |
| March 31, 2016 | 1.572M |
| December 31, 2015 | 0.186M |
| September 30, 2015 | 0.658M |
| June 30, 2015 | 2.185M |
| March 31, 2015 | 26.46M |
| December 31, 2014 | 10.02M |
| September 30, 2014 | 0.00 |
| June 30, 2014 | 0.002M |
| March 31, 2014 | 22.61M |
| December 31, 2013 | 1.057M |
| September 30, 2013 | 1.415M |
| June 30, 2013 | 1.103M |
| March 31, 2013 | 11.50M |
| December 31, 2012 | 2.509M |
| September 30, 2012 | -0.1069M |
| June 30, 2012 | -0.7328M |
| March 31, 2012 | 14.10M |
| December 31, 2011 | -0.0195M |
| September 30, 2011 | -0.0171M |
Cash From Financing Definition
Cash flow from financing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall financing activities of the company. A few examples of financing activities include common stock issuance, total dividends paid, and net debt issuance.
Cash from Financing (Quarterly) Range, Past 5 Years
-1.048M
Minimum
Sep 2020
41.91M
Maximum
Mar 2021
6.073M
Average
0.879M
Median
Sep 2019
Cash from Financing (Quarterly) Benchmarks
| Compugen Ltd | -- |
| Pluri Inc | 0.00 |
| XTL Biopharmaceuticals Ltd | -- |
| Can Fite Biofarma Ltd | -- |
| BiomX Inc | -1.324M |
Cash from Financing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | 4.991M |
| Cash from Investing (Quarterly) | -20.40M |
| Free Cash Flow | -22.90M |
| Free Cash Flow Per Share (Quarterly) | 0.0692 |
| Free Cash Flow to Equity (Quarterly) | 6.736M |
| Free Cash Flow Yield | -52.45% |